February 17, 2022
Even a casual, unscientific survey of recent PTAB decisions shows a clear and unmistakable trend: shorter decisions, with little or no discussion of issues not specifically
Read more
February 11, 2022
A typical Markush group is structured as “selected from the group consisting of A, B, and C.” The language is closed in nature due to the
Read more
February 3, 2022
In Ex parte Kano (Appeal No. 2021-004640), the Patent Trial and Appeal Board (“Board”) rejected an Examiner’s finding of obviousness that was premised on a nonoverlapping
Read more
January 28, 2022
In Ex parte Scheich (Appeal No. 2021-003495), the examiner rejected the claims as obvious over a combination of two references. The PTAB reversed. Independent claim 1
Read more
January 20, 2022
Ex parte Myers is a recent decision of the Patent Trial and Appeal Board (PTAB) addressing enablement and written description of a claim amended to recite
Read more
January 14, 2022
In Ex parte Watabe, No. 2020-005979 (P.T.A.B. Sep. 28, 2021), the Patent Trial and Appeal Board (PTAB) reversed an Examiner’s rejection of claims directed to a
Read more
January 7, 2022
In Ex parte Zhang (Appeal No. 2021-005022), the Patent Trial and Appeal Board (“Board”) rejected an Examiner’s finding of obviousness that was premised on an unappreciated
Read more
December 29, 2021
In Ex parte Price (Appeal 2021-003888), the Patent Trial and Appeal Board (“Board”) reversed the Examiner’s obviousness rejection because of Appellant’s successful showing of unexpected results.
Read more
December 22, 2021
In Ex parte Ruvolo (Appeal No. 2021-001708), the examiner rejected nucleotide claims as anticipated under § 102. The PTAB reversed. Independent claim 12 recited (in part):
Read more
December 13, 2021
AstraZeneca AB v. Mylan Pharm., 2021-1729 (Fed. Cir. Dec. 8, 2021), is a recent decision of the Federal Circuit interpreting the scope of a numerical limitation
Read more